TAK 411
Alternative Names: Hypersialylated immune globulin G -Takeda; Hypersialylated immunoglobulin G - Takeda; TAK-411Latest Information Update: 18 Jun 2025
At a glance
- Originator Takeda
- Class Immunoglobulins; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic inflammatory demyelinating polyradiculoneuropathy
Most Recent Events
- 14 May 2025 Phase-II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (Treatment-experienced) in Japan (IV) (NCT06798012)
- 04 Feb 2025 Takeda plans a phase II CASCA trial for Chronic inflammatory demyelinating polyradiculoneuropathy (Treatment-experienced) in USA (PO), in February 2025 (NCT06798012)
- 04 Feb 2025 Preclinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV), before February 2025